Ion Exchange revamped its reporting, splitting Engineering into Treatment Solutions, Industrial Products, and Lifecycle Services, and renaming Chemicals to Specialty Chemicals for enhanced transparency.

Q1 FY'27 operating income rose 20% to INR 701 Cr, but EBITDA fell 49% to INR 32 Cr, with PAT at INR 3 Cr.

Profitability was notably impacted by legacy projects and initial costs from the new Roha plant.

The company holds a strong order book of INR 2,473 Cr, alongside a new INR 431.6 Cr Hyundai contract.

Management acknowledged Q1 challenges but expressed optimism, focusing on improved execution, scaling new capacities (resins, membranes), and targeting high-tech areas like semiconductors and green hydrogen for long-term profitable growth.